002082.SHE Wanbangde Pharmaceutical Holding Group Co Ltd
- Market cap
- CNY 6.01B
- P/E
- -
- P/B
- 2.36x
- ROE
- 1.3%
- Dividend yield
- 0.79%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002082.SHE undervalued?
Graham numberThe Graham number of Wanbangde Pharmaceutical Holding Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Wanbangde Pharmaceutical Holding Group Co Ltd fundamental analysis
No fundamental analysis for Wanbangde Pharmaceutical Holding Group Co Ltd yet.
Wanbangde Pharmaceutical Holding Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Wanbangde Pharmaceutical Holding Group Co Ltd
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Manufacturing Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascular diseases; and nervous, respiratory, mental, and digestive syste…
Full company profileWanbangde Pharmaceutical Holding Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Wanbangde Pharmaceutical Holding Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.18B | 14.6B | 736M | 16.7B | 13.7B | 1.93B | 1.79B | 1.54B | 1.44B | 1.14B | 1.01B |
| Gross Profit | 175M | 226M | 575M | 1.43B | 1.34B | 931M | 934M | 624M | 596M | 1.14B | 413M |
| Operating Income | 75.2M | 117M | 189M | 517M | 347M | 375M | 129M | 27.0M | 60.1M | -172M | 51.5M |
| EBITDA | 138M | 171M | 252M | 680M | 513M | 492M | 239M | 172M | 195M | -77.2M | 51.5M |
| Net Income | 69.7M | 98.2M | 162M | 295M | 285M | 167M | 93.3M | 49.2M | 55.4M | -199M | 33.7M |
| EPS | 0.29 | 0.41 | 0.45 | 0.59 | 0.47 | 0.27 | 0.15 | 0.08 | 0.09 | -0.32 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 1.66B | 2.10B | 2.85B | 3.80B | 5.66B | 4.37B | 4.22B | 4.30B | 4.33B | 4.39B | 4.31B |
| Total Liabilities | 262M | 497M | 1.12B | 1.89B | 2.80B | 1.63B | 1.40B | 1.54B | 1.57B | 1.78B | 1.69B |
| Shareholders' Equity | 1.38B | 1.42B | 1.49B | 1.64B | 2.62B | 2.60B | 2.69B | 2.66B | 2.67B | 2.52B | 2.54B |
| Cash & Short-term Investments | 557M | 281M | 497M | 651M | 574M | 912M | 468M | 227M | 170M | 547M | 653M |
| Total Debt | 112M | 89.6M | 532M | 1.36B | 1.86B | 841M | 863M | 918M | 970M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 311M | -17.6M | 135M | -249M | 151M | 22.1M | -240M | -72.9M | 120M | 604M | - |
| Capital Expenditure | 9.03M | 20.9M | 200M | 406M | 559M | 277M | 167M | 129M | 88.4M | 290M | 49.4M |
| Free Cash Flow | 302M | -38.5M | -64.2M | -655M | -408M | -255M | -407M | -202M | 31.8M | 314M | 164M |
| Ratios | |||||||||||
| ROE | 5.0% | 6.9% | 10.9% | 18.0% | 10.9% | 6.4% | 3.5% | 1.9% | 2.1% | -7.9% | 1.3% |
| ROA | 4.2% | 4.7% | 5.7% | 7.7% | 5.0% | 3.8% | 2.2% | 1.1% | 1.3% | -4.5% | 0.8% |
| Net Profit Margin | 0.8% | 0.7% | 22.0% | 1.8% | 2.1% | 8.6% | 5.2% | 3.2% | 3.8% | -17.4% | 3.3% |
| Debt to Equity | 0.08x | 0.06x | 0.36x | 0.83x | 0.71x | 0.32x | 0.32x | 0.35x | 0.36x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Wanbangde Pharmaceutical Holding Group Co Ltd dividends
- Dividend yield
- 0.79%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 11, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 47.7M | 0.08 | - |
| 2024 | CNY 90.8M | 0.15 | 163.9% |
| 2023 | CNY 122M | 0.20 | 248.0% |
| 2022 | CNY 43.9M | 0.07 | 47.1% |
| 2021 | CNY 123M | 0.20 | 73.8% |
| 2020 | CNY 92.7M | 0.15 | 32.5% |
| 2019 | CNY 50.2M | 0.10 | 17.0% |
| 2018 | CNY 24.7M | 0.07 | 15.2% |
| 2017 | CNY 59.5M | 0.25 | 60.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on Jun 10, 2008.
Who owns Wanbangde Pharmaceutical Holding Group Co Ltd
- Insiders 53.51%
- Institutions 2.70%
- Public & others 43.79%
- Shares outstanding 612M
- Free float 284M
Wanbangde Pharmaceutical Holding Group Co Ltd company profile
- Company name
- Wanbangde Pharmaceutical Holding Group Co Ltd
- Ticker
- 002082.SHE
- ISIN
- CNE000001P94
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Nov 20, 2006
- Sector
- Healthcare
- Industry
- Metals & Mining
- Employees
- 1,348
- Fiscal year end
- December
- Address
- No. 28, Baizhang North Road, Taizhou, China, 317500
- Phone
- 86 57 6861 83999
- Website
- wepon.com.cn
About Wanbangde Pharmaceutical Holding Group Co Ltd
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Manufacturing Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascular diseases; and nervous, respiratory, mental, and digestive system diseases. The company also develops and sells human orthopedic implant devices, including orthopedic implant devices comprised of thoracolumbar fusion, cervical fusion, spinal internal fixation systems, independent fusion devices, unicompartmental knee joints, etc.; medical equipment; disposable sterile medical polymer consumables; and hospital engineering services. The company was formerly known as Wanbangde New Building Materials Co., Ltd. and changed its name to Wanbangde Pharmaceutical Holding Group Co., Ltd. in April 2020. Wanbangde Pharmaceutical Holding Group Co., Ltd. was founded in 1985 and is headquartered in Taizhou, China.
Wanbangde Pharmaceutical Holding Group Co Ltd management
3- Mr. Shouming ZhaoActing Board Secretary, GM & Chairman of the Board · born 1964
- Mr. Zheng JinChief Financial Officer & Accounting Supervisor · born 1982
- Mr. Tongke LiuExecutive VP & Director · born 1965